What is the main business of Genetykalab?

The main business activity of Genetykalab focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on May 29, 2023.

Where is the headquarters located?

The headquarters is located at: ul. Cybernetyki 19B, 02-677 Warszawa.

Who is on the management board?

The management board includes Aleksandra Brehova (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

How much revenue was generated?

The company reported a revenue of $1,690,119 in 2025, which is an increase of 50.3% compared to 2024.

Yes, in 2025 the company was profitable, achieving a net profit of $812,774, meaning the company increased its profit by 260.3%.

What is the main operating cost?

The largest operating cost category falls under cost of goods and materials sold. This category amounted to $605,007 in 2025, representing 91% of all operating expenses.

Genetykalabsp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2023-05-29

Share capital

5,000.00 PLN

Registered address

ul. Cybernetyki 19B/331, 02-677 Warszawa, Poland

Electronic delivery address

AE:PL-39432-88731-UAEAG-26

Financials

Revenue history (in k)

Filing timeliness

Financial statements were filed on time, on average 120 days early.

202520/03/2026
202410/03/2025
202320/03/2024

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 1.69mMedianUSD 55.24kAverageUSD 2.71m

Net profit

This companyUSD 812.77kMedianUSD -1.27kAverageUSD -91.85k

Operating costs

This companyUSD 665.75kMedianUSD 65.85kAverageUSD 2.66m

Assets

This companyUSD 1.31mMedianUSD 133.19kAverageUSD 3.03m

Industry

Authorized Representatives

Aleksandra Brehova – President of the Management Board

Jevgēnijs Brehovs – Attorney-in-fact (sole)

Manner of representation

Each member of the management board is authorized to make declarations of will on behalf of the company independently.

Ownership

Owner	Shares	Share value	Stake
Limarr Enterprise sp. z o.o.	80	$1,080.50	80%
Novaprep Ltd	20	$270.12	20%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2023-06-06.

Bank Pekao SA
60 1240 1040 1111 0011 2670 2238
Bank Pekao SA
24 1240 1040 1978 0011 2670 2313
Bank Pekao SA
16 1240 1040 1789 0011 2670 2401

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
FamicordtxS.A.	$1,365,068.41	famicordtx.com
Orphinic ScientificS.A.	$518,429.97	orphinic.com
Proper Medical Writingsp. z o.o.	$464,661.64	propermedicalwriting.com
Medicofarma BiotechS.A.	$314,882.33	medicofarmabiotech.pl
Explorna Therapeuticssp. z o.o.	$304,662.00	explorna.com
Frontline BiosciencesS.A.	$219,186.29	frontlinebiosciences.com
AI Corelabsp. z o.o.	$128,365.55	aicorelab.com
ModicaP.S.A.	$103,400.72	modica.bio
WPD Pharmaceuticalssp. z o.o.	$90,822.78	wpdpharmaceuticals.com
WPD PharmaceuticalsS.A.	$87,561.70	wpdpharmaceuticals.pl